NASDAQ:ORGS Orgenesis (ORGS) Stock Price, News & Analysis $1.20 -0.03 (-2.45%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSustainabilityTrends About Orgenesis Stock (NASDAQ:ORGS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Orgenesis alerts:Sign Up Key Stats Today's Range$1.12▼$1.3350-Day Range N/A52-Week Range$1.03▼$10.80Volume10,517 shsAverage Volume24,011 shsMarket Capitalization$5.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Read More… The most serious warning of my career (Ad)With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. Click here now to grab your seat now. Orgenesis Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks66th Percentile Overall ScoreORGS MarketRank™: Orgenesis scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Orgenesis.Read more about Orgenesis' stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Read more about Orgenesis' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.29% of the float of Orgenesis has been sold short.Short Interest Ratio / Days to CoverOrgenesis has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Orgenesis has recently decreased by 39.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOrgenesis does not currently pay a dividend.Dividend GrowthOrgenesis does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.49 Percentage of Shares Shorted0.29% of the float of Orgenesis has been sold short.Short Interest Ratio / Days to CoverOrgenesis has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Orgenesis has recently decreased by 39.96%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News SentimentN/A News SentimentOrgenesis has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Orgenesis this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for ORGS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Orgenesis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.66% of the stock of Orgenesis is held by insiders.Percentage Held by InstitutionsOnly 22.56% of the stock of Orgenesis is held by institutions.Read more about Orgenesis' insider trading history. Receive ORGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter. Email Address ORGS Stock News HeadlinesOrgenesis commences trading on OTCQX Best MarketOctober 22, 2024 | markets.businessinsider.comOrgenesis Commences Trading on OTCQX® Best MarketOctober 21, 2024 | markets.businessinsider.comUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?October 31, 2024 | Behind the Markets (Ad)Orgenesis (NASDAQ:ORGS) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.com45O.SG,0P0001J8IU,0 (45O.SG)September 24, 2024 | au.finance.yahoo.comWhy Orgenesis (ORGS) Stock Is Down 23% TodaySeptember 24, 2024 | msn.comOrgenesis Inc.: Orgenesis Announces Reverse Stock SplitSeptember 23, 2024 | finanznachrichten.deOrgenesis Approves 1-for-10 Reverse Stock SplitSeptember 23, 2024 | markets.businessinsider.comSee More Headlines ORGS Stock Analysis - Frequently Asked Questions How have ORGS shares performed this year? Orgenesis' stock was trading at $4.08 at the start of the year. Since then, ORGS stock has decreased by 70.7% and is now trading at $1.1950. View the best growth stocks for 2024 here. How were Orgenesis' earnings last quarter? Orgenesis Inc. (NASDAQ:ORGS) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($2.30) earnings per share for the quarter. The company had revenue of $0.25 million for the quarter. When did Orgenesis' stock split? Shares of Orgenesis reverse split before market open on Wednesday, September 25th 2024. The 1-10 reverse split was announced on Monday, September 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Does Orgenesis have any subsidiaries? The following companies are subsidiaries of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc. How do I buy shares of Orgenesis? Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Orgenesis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Orgenesis investors own include NVIDIA (NVDA), Energy Transfer (ET), BioLineRx (BLRX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and Enbridge (ENB). Company Calendar Last Earnings8/08/2024Today10/31/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORGS CUSIPN/A CIK1460602 Webwww.orgenesis.com Phone(480) 659-6404FaxN/AEmployees150Year Founded2008Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,360,000.00 Net Margins-6,857.25% Pretax Margin-4,447.89% Return on EquityN/A Return on Assets-190.67% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$662,000.00 Price / Sales8.88 Cash FlowN/A Price / Cash FlowN/A Book Value($6.58) per share Price / Book-0.19Miscellaneous Outstanding Shares4,799,000Free Float4,527,000Market Cap$5.88 million OptionableOptionable Beta1.21 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ORGS) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.